RaysightMed

RaysightMed is an innovative medical enterprise that develops AI intelligence and precision diagnosis and treatment for cardiovascular and cerebrovascular diseases, starting with the research and development of CT-FFR (non-invasive fractional flow reserve). Since its establishment more than three years ago, it has completed five rounds of financing. Currently, the company's developed products have wide applications in the detection of cardiovascular and cerebrovascular diseases. Raysightmed is researching and developing an intelligent medical platform based on artificial intelligence, simulation, and cloud computing to deeply mine information from medical data for more accurate disease assessment and treatment guidance. RaysightMed’s product services cover the entire spectrum of cardiovascular, cerebrovascular, and peripheral vascular diagnosis and treatment scenarios, achieving refined application coverage from preoperative evaluation, risk analysis, surgical planning, consumables simulation, consumables selection, intraoperative navigation, effect evaluation, to postoperative follow-up. According to reports, in addition to the Raysight FFR, several other products, including a coronary artery intelligent post-processing platform, a cerebrovascular blood supply function evaluation platform, and a peripheral vascular imaging intelligent processing platform, are in the final stages of clinical trials and nearing market access. It is expected that by 2022, the first integrated, precise, non-invasive, and intelligent full-course diagnosis and treatment management platform for cardiovascular and cerebrovascular diseases will be fully implemented. The market value of the entire product portfolio is expected to reach hundreds of billions of RMB.